Actinium Pharmaceuticals Inc. (ATNM) 6.05 $ATNM
Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Business Wire - Wed Jul 30, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jul 24, 9:49AM CDT
RedChip Companies, Inc. ("RedChip", an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program will feature two emerging growth companies on Fox Business nationwide on Thursday, July 24, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, July 26, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, July 27, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday July 27, 2014 at 3:30 p.m. HKT.
CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program
Business Wire - Wed Jul 16, 9:54AM CDT
Headline of release should read: Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program). Subhead of release should read: Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies (instead of Actinium Pharmaceuticals Initiates Development Of Actinium 225 Labeled Antibody For Hematologic Malignancies). Also, a sentence was added to the end of the first paragraph.
Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program
Business Wire - Wed Jul 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications.
Actinium reports exercise of additional 157,123 shares in underwriters' option, with stronger balance sheet to support late-stage pipeline development
M2 - Fri Jul 11, 5:40AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) disclosed on Thursday that the underwriters of its public offering have exercised their over-allotment option to purchase an additional 157,123 shares.
Actinium Announces Exercise of Greenshoe Option
Business Wire - Thu Jul 10, 3:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the underwriters of the previously announced offering of 1,670,000 common shares of Actinium exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. The public offering previously closed on June 30, 2014.
Baylor Oncology Medical Director Joins Actinium's Iomab-B Scientific Advisory Board
Business Wire - Mon Jul 07, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab(TM)-B. Iomab(TM)-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.
Actinium Joins Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jul 01, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, joined the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) on June 27, 2014.
Actinium concludes public offering at USD7.50 per share
M2 - Tue Jul 01, 3:18AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Monday the completion of its public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Closes Public Offering of Common Shares
Business Wire - Mon Jun 30, 10:28AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,500 shares of common stock solely to cover over-allotments, if any.
Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum's Newly Established Iomab-B Scientific Advisory Board
Business Wire - Thu Jun 26, 8:22AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the establishment of its Scientific Advisory Board (SAB) for Iomab(TM)-B comprised of several preeminent clinicians in the fields of oncology, hematology, and bone marrow transplant. Combining the wealth of clinical, strategic, and scientific experience in cancer drug development, the Scientific Advisory Board is well suited to support the company's development strategy for the advancement of Iomab(TM)-B, the Company's lead radioimmunotherapy asset, in a Phase 3 trial to potentially address the significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications.
Actinium prices public offering at USD7.50 per share
M2 - Thu Jun 26, 5:09AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Wednesday that it has priced a public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Prices $12.5 Million Public Offering of Common Shares
Business Wire - Wed Jun 25, 7:30AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions.
Actinium plans to launch public offering of common stock
M2 - Wed Jun 25, 5:50AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) said on Tuesday that it plans to issue shares of its common stock in a public offering.
Actinium Announces Proposed Public Offering of Common Shares
Business Wire - Tue Jun 24, 3:01PM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company" (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium.
Actinium's Actimab-A and Alpha-Particle Immunotherapy Platform Further Validated at Society for Nuclear Medicine Annual Meeting
Business Wire - Tue Jun 24, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, provided highlights from an educational session featuring Actimab-A, a radiolabeled antibody currently in a Phase I/II clinical trial, at the 2014 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in St. Louis, MO.
Actinium to Present at the 2014 BIO International Convention in San Diego on June 26th
Business Wire - Mon Jun 23, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present a corporate update at the 2014 BIO International Convention in San Diego, CA on June 26th, 2014.
Actinium Set to Join Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jun 17, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is set to join the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
Actinium Engages a Leading CRO to Support Phase 3 Trial of Iomab-B
Business Wire - Mon Jun 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it has executed an agreement with ACT Oncology, a full-service clinical research organization (CRO) specializing in providing oncology drug development support for biotech, pharmaceutical and non-profit oncology organizations, to utilize their services for a number of clinical development-related projects. This agreement includes the preparations for the Phase 3 clinical trial of Iomab-B, a myeloconditioning drug for bone marrow transplant preparation.
Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Business Wire - Wed Jul 30, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML). RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Jul 24, 9:49AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"TM) television program will feature two emerging growth companies on Fox Business nationwide on Thursday, July 24, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, July 26, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, July 27, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday July 27, 2014 at 3:30 p.m. HKT. CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program
Business Wire - Wed Jul 16, 9:54AM CDT
Headline of release should read: Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program). Subhead of release should read: Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies (instead of Actinium Pharmaceuticals Initiates Development Of Actinium 225 Labeled Antibody For Hematologic Malignancies). Also, a sentence was added to the end of the first paragraph.
Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program
Business Wire - Wed Jul 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Actinium reports exercise of additional 157,123 shares in underwriters' option, with stronger balance sheet to support late-stage pipeline development
M2 - Fri Jul 11, 5:40AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) disclosed on Thursday that the underwriters of its public offering have exercised their over-allotment option to purchase an additional 157,123 shares.
Actinium Announces Exercise of Greenshoe Option
Business Wire - Thu Jul 10, 3:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the underwriters of the previously announced offering of 1,670,000 common shares of Actinium exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. The public offering previously closed on June 30, 2014. Baylor Oncology Medical Director Joins Actinium's Iomab-B Scientific Advisory Board
Business Wire - Mon Jul 07, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab(TM)-B. Iomab(TM)-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications. Actinium Joins Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jul 01, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, joined the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) on June 27, 2014. Actinium concludes public offering at USD7.50 per share
M2 - Tue Jul 01, 3:18AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Monday the completion of its public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Closes Public Offering of Common Shares
Business Wire - Mon Jun 30, 10:28AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,500 shares of common stock solely to cover over-allotments, if any. Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum's Newly Established Iomab-B Scientific Advisory Board
Business Wire - Thu Jun 26, 8:22AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the establishment of its Scientific Advisory Board (SAB) for Iomab(TM)-B comprised of several preeminent clinicians in the fields of oncology, hematology, and bone marrow transplant. Combining the wealth of clinical, strategic, and scientific experience in cancer drug development, the Scientific Advisory Board is well suited to support the company's development strategy for the advancement of Iomab(TM)-B, the Company's lead radioimmunotherapy asset, in a Phase 3 trial to potentially address the significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications. Actinium prices public offering at USD7.50 per share
M2 - Thu Jun 26, 5:09AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) reported on Wednesday that it has priced a public offering of 1,670,000 common shares at USD7.50 per share.
Actinium Prices $12.5 Million Public Offering of Common Shares
Business Wire - Wed Jun 25, 7:30AM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock solely to cover over-allotments, if any. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions. Actinium plans to launch public offering of common stock
M2 - Wed Jun 25, 5:50AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) said on Tuesday that it plans to issue shares of its common stock in a public offering.
Actinium Announces Proposed Public Offering of Common Shares
Business Wire - Tue Jun 24, 3:01PM CDT
Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares are being offered by Actinium. Actinium's Actimab-A and Alpha-Particle Immunotherapy Platform Further Validated at Society for Nuclear Medicine Annual Meeting
Business Wire - Tue Jun 24, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, provided highlights from an educational session featuring Actimab-A, a radiolabeled antibody currently in a Phase I/II clinical trial, at the 2014 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in St. Louis, MO. Actinium to Present at the 2014 BIO International Convention in San Diego on June 26th
Business Wire - Mon Jun 23, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present a corporate update at the 2014 BIO International Convention in San Diego, CA on June 26th, 2014. Actinium Set to Join Russell 3000(R), Russell 2000(R), Russell Global, and Russell Micro-Cap(R) Indexes
Business Wire - Tue Jun 17, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is set to join the broad-market Russell 3000(R) Index as well as the Russell 2000(R) , Russell Global and Russell Microcap(R) indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes. Actinium Engages a Leading CRO to Support Phase 3 Trial of Iomab-B
Business Wire - Mon Jun 16, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it has executed an agreement with ACT Oncology, a full-service clinical research organization (CRO) specializing in providing oncology drug development support for biotech, pharmaceutical and non-profit oncology organizations, to utilize their services for a number of clinical development-related projects. This agreement includes the preparations for the Phase 3 clinical trial of Iomab-B, a myeloconditioning drug for bone marrow transplant preparation. 
